share_log

The Analyst Landscape: 5 Takes On TScan Therapeutics

Benzinga ·  Dec 11 09:01

Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings50000
Last 30D20000
1M Ago20000
2M Ago10000
3M Ago00000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.6, a high estimate of $15.00, and a low estimate of $11.00. Holding firm without variation, the current average remains at the previous average price target.

bigjpg

Investigating Analyst Ratings: An Elaborate Study

The standing of TScan Therapeutics among...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment